Division of Infectious Diseases, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, University of Linköping, Linköping, Sweden.
PLoS One. 2011 Mar 31;6(3):e18220. doi: 10.1371/journal.pone.0018220.
Despite the good prognosis of erythema migrans (EM), some patients have persisting symptoms of various character and duration post-treatment. Several factors may affect the clinical outcome of EM, e.g. the early interaction between Borrelia (B.) burgdorferi and the host immune response, the B. burgdorferi genotype, antibiotic treatment as well as other clinical circumstances. Our study was designed to determine whether early cytokine expression in the skin and in peripheral blood in patients with EM is associated with the clinical outcome.
A prospective follow-up study of 109 patients with EM was conducted at the Åland Islands, Finland. Symptoms were evaluated at 3, 6, 12 and 24 months post-treatment. Skin biopsies from the EM and healthy skin were immunohistochemically analysed for expression of interleukin (IL)-4, IL-10, IL-12p70 and interferon (IFN)-γ, as well as for B. burgdorferi DNA. Blood samples were analysed for B. burgdorferi antibodies, allergic predisposition and levels of systemic cytokines.
None of the patients developed late manifestations of Lyme borreliosis. However, at the 6-month follow-up, 7 of 88 patients reported persisting symptoms of diverse character. Compared to asymptomatic patients, these 7 patients showed decreased expression of the Th1-associated cytokine IFN-γ in the EM biopsies (p=0.003). B. afzelii DNA was found in 48%, B. garinii in 15% and B. burgdorferi sensu stricto in 1% of the EM biopsies, and species distribution was the same in patients with and without post-treatment symptoms. The two groups did not differ regarding baseline patient characteristics, B. burgdorferi antibodies, allergic predisposition or systemic cytokine levels.
Patients with persisting symptoms following an EM show a decreased Th1-type inflammatory response in infected skin early during the infection, which might reflect a dysregulation of the early immune response. This finding supports the importance of an early, local Th1-type response for optimal resolution of LB.
尽管红斑性游走疹(EM)预后良好,但部分患者在治疗后仍会出现各种性质和持续时间的持续性症状。多种因素可能会影响 EM 的临床结果,例如:早期伯氏疏螺旋体(B.)与宿主免疫反应的相互作用、伯氏疏螺旋体的基因型、抗生素治疗以及其他临床情况。我们的研究旨在确定 EM 患者的皮肤和外周血中早期细胞因子表达是否与临床结果相关。
在芬兰奥兰群岛进行了一项前瞻性随访研究,共纳入 109 例 EM 患者。在治疗后 3、6、12 和 24 个月评估症状。采用免疫组化法分析 EM 和健康皮肤的皮肤活检样本中白细胞介素(IL)-4、IL-10、IL-12p70 和干扰素(IFN)-γ的表达情况,以及伯氏疏螺旋体 DNA。分析血液样本中的伯氏疏螺旋体抗体、过敏倾向和全身细胞因子水平。
无患者出现晚期莱姆病表现。然而,在 6 个月随访时,88 例患者中有 7 例报告存在不同性质的持续性症状。与无症状患者相比,这 7 例患者 EM 活检中 Th1 相关细胞因子 IFN-γ的表达减少(p=0.003)。EM 活检中发现 48%的 B. afzelii DNA、15%的 B. garinii DNA 和 1%的 B. burgdorferi sensu stricto DNA,且治疗后有症状和无症状患者的种系分布相同。两组患者在基线患者特征、伯氏疏螺旋体抗体、过敏倾向或全身细胞因子水平方面无差异。
EM 后持续出现症状的患者在感染早期感染皮肤中表现出 Th1 型炎症反应减少,这可能反映了早期免疫反应的失调。这一发现支持早期局部 Th1 型反应对最佳解决 LB 的重要性。